AI assistant
BIODESIX INC — Director's Dealing 2020
Nov 4, 2020
34472_dirs_2020-11-03_6c308218-0d48-4164-8efd-3bd1331039d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2020-07-01
Reporting Person: MASSARANY HANY (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-10-30 | Common Stock | P | 7500 | $18.00 | Acquired | 7500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-07-01 | Stock Options (Right to buy) | $6.83 | A | 35158 | Acquired | 2030-06-30 | Common Stock (35158) | Direct |
| 2020-07-01 | Restricted Stock Units | $6.83 | A | 26368 | Acquired | 2030-06-30 | Common Stock (26368) | Direct |
Footnotes
F1: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F2: This option vests in 12 successive, equal monthly installments measured from July 1, 2020.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Common Stock ("Common Stock"). These RSUs vest 40% on July 1, 2022, and the remaining 60% in 36 successive, equal monthly installments measured from July 1, 2022.